Guardant Health , Inc. (NASDAQ:GH) saw its shares surge 6.9% after the precision oncology company reported better-than-expected first quarter results and raised its full-year revenue guidance.
The company posted Q1 adjusted earnings per share of -$0.49, beating analyst estimates of -$0.75 by $0.26. Revenue for the quarter came in at $203.5 million, up 21% YoY and surpassing the consensus estimate of $190.01 million.
Guardant Health’s strong performance was driven by growth across its oncology, screening, and biopharma & data segments. Oncology revenue increased 20% to $150.6 million, while biopharma & data revenue grew 21% to $45.4 million. The company also reported $5.7 million in screening revenue from approximately 9,000 Shield screening tests.
Looking ahead, Guardant Health raised its full-year 2025 revenue guidance to $880-$890 million, representing growth of 19% to 20% compared to 2024. This outlook is above the analyst consensus of $857.7 million.
The company also expects oncology revenue to grow approximately 18% YoY in 2025, up from its previous guidance of 15% growth. Screening revenue is now projected to be in the range of $40 to $45 million, driven by Shield volume of 52,000 to 58,000 tests.
Guardant Health maintained its expectation for biopharma & data revenue growth in the low double-digit range for the year.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.